QuidelOrtho to Sell Testing Unit in $1.5B Deal: Report
QuidelOrtho is planning to divest a testing business unit for $1.5 billion, according to a Financial Times report.
QuidelOrtho is moving to shed one of its testing units in a deal valued at approximately $1.5 billion, the Financial Times reported, marking a significant strategic shift for the diagnostics company as it looks to reshape its portfolio and sharpen its competitive focus.
The planned divestiture signals that QuidelOrtho's leadership is under pressure to streamline operations and unlock value for shareholders. Selling a major business unit of this scale could free up capital for debt reduction, reinvestment in core product lines, or other strategic priorities — though the company has not publicly detailed its intended use of proceeds based on available reporting.
Read more CI&T Joins Anthropic's Claude Partner Network →
QuidelOrtho, formed from the 2022 merger of Quidel Corporation and Ortho Clinical Diagnostics, has been navigating a challenging post-pandemic landscape in which demand for rapid testing products normalized sharply from COVID-era highs. A $1.5 billion asset sale would represent a meaningful step in right-sizing the combined company's structure for current market conditions.
The diagnostics sector broadly has seen consolidation and portfolio rationalization as companies that scaled aggressively during the pandemic seek sustainable growth paths. QuidelOrtho's reported move fits that wider industry pattern, potentially attracting interest from strategic acquirers or private equity buyers looking to gain scale in the testing space.
Continue reading at SeekingAlpha.
